Depemokimab, a monoclonal antibody that targets IL-5, is the first ultra-long-acting biologic to be evaluated in phase III trials.1,2,3 IL-5 is a key cytokine (protein) in type 2 inflammation.1,5 ...

GSK's depemokimab accepted for review by Health Canada for the treatment of asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps. Newswire.ca - Mon May 26, 8:10AM CDT.

GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and ...

SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster abstract ...

Depemokimab is an ultra-long acting biologic with high binding affinity for interleukin-5. This extended half-life allows for twice-yearly (every 6 months) subcutaneous administration.

Depemokimab is not currently approved in any country for either of these indications. The ANCHOR-1 and ANCHOR-2 clinical trials assessed the safety and efficacy of depemokimab in patients with CRSwNP.

In the study, "Efficacy and Safety of Twice-Yearly Depemokimab in Chronic Rhinosinusitis with Nasal Polyps (ANCHOR-1 and ANCHOR-2)," published in The Lancet, researchers conducted randomized ...

He highlighted the SWIFT and ANCHOR trials, which demonstrated depemokimab's potential to suppress interleukin-5 (IL-5), a key driver of type 2 inflammation, with sustained effects from just two ...

Today, GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $76.59 billion and impressive gross profit margins of 71.81%, announced that the US Food and Drug ...

Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Get our list of 10 ...